Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Vertex Pharmaceuticals Inc / Ma (VRTX) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Vertex Pharmaceuticals Inc / Ma. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 875320.
Total stock buying since 2014: $14,032,945.
Total stock sales since 2014: $1,196,910,074.
Total stock option exercises since 2014: $345,948,365.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 15,000 | $5,843,150 | 36,186 | $17,560,365 | 0 | $0 |
| 2024 | 0 | $0 | 148,610 | $67,869,390 | 14,306 | $1,623,040 |
| 2023 | 0 | $0 | 293,658 | $101,547,730 | 106,203 | $13,301,242 |
| 2022 | 0 | $0 | 299,056 | $84,212,962 | 129,539 | $14,304,907 |
| 2021 | 25,000 | $4,926,050 | 80,192 | $17,017,085 | 3,884 | $336,043 |
| 2020 | 15,000 | $3,263,745 | 823,381 | $212,996,253 | 593,830 | $68,989,498 |
| 2019 | 0 | $0 | 749,106 | $142,436,412 | 640,272 | $64,836,003 |
| 2018 | 0 | $0 | 677,893 | $111,360,024 | 569,594 | $48,688,330 |
| 2017 | 0 | $0 | 1,829,749 | $255,631,975 | 1,303,112 | $81,084,922 |
| 2016 | 0 | $0 | 425,204 | $38,606,160 | 329,295 | $11,861,367 |
| 2015 | 0 | $0 | 1,169,000 | $146,404,893 | 1,011,116 | $40,701,778 |
| 2014 | 0 | $0 | 10,500 | $1,266,825 | 10,500 | $221,235 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-01-25 | Lee Yuchun (Director) | Sale | 4,000 | 313.95 | 1,255,800 |
| 2023-01-25 | Lee Yuchun (Director) | Option Ex | 4,000 | 72.14 | 288,560 |
| 2023-01-24 | Lee Yuchun (Director) | Sale | 4,000 | 312.82 | 1,251,300 |
| 2023-01-24 | Lee Yuchun (Director) | Option Ex | 4,000 | 72.14 | 288,560 |
| 2023-01-23 | Lee Yuchun (Director) | Sale | 2,129 | 312.02 | 664,290 |
| 2023-01-23 | Lee Yuchun (Director) | Option Ex | 2,129 | 72.14 | 153,586 |
| 2022-11-15 | Altshuler David (EVP, Global Research and CSO) | Sale | 102 | 308.61 | 31,476 |
| 2022-10-24 | Bhatia Sangeeta N. (Director) | Sale | 621 | 310.00 | 192,510 |
| 2022-10-18 | Sanna Bastiano (EVP, Cell & Genetic Therapies) | Sale | 1,791 | 300.93 | 538,965 |
| 2022-08-15 | Liu Joy (SVP, General Counsel) | Sale | 3,747 | 303.13 | 1,135,846 |
| 2022-08-15 | Kewalramani Reshma (CEO & President) | Sale | 11,689 | 305.06 | 3,565,846 |
| 2022-08-15 | Arbuckle Stuart A (EVP, COO) | Sale | 22,173 | 303.05 | 6,719,483 |
| 2022-08-15 | Arbuckle Stuart A (EVP, COO) | Option Ex | 6,571 | 155.57 | 1,022,250 |
| 2022-08-10 | Liu Joy (SVP, General Counsel) | Sale | 36 | 300.32 | 10,811 |
| 2022-08-10 | Arbuckle Stuart A (EVP, COO) | Sale | 180 | 301.17 | 54,209 |
| 2022-08-10 | Arbuckle Stuart A (EVP, COO) | Option Ex | 64 | 155.57 | 9,956 |
| 2022-08-09 | Liu Joy (SVP, General Counsel) | Sale | 946 | 300.00 | 283,800 |
| 2022-08-09 | Tatsis Ourania (EVP, Chief Reg. & Quality Off.) | Sale | 1,400 | 299.68 | 419,554 |
| 2022-08-09 | Arbuckle Stuart A (EVP, COO) | Sale | 5,690 | 300.98 | 1,712,547 |
| 2022-08-09 | Arbuckle Stuart A (EVP, COO) | Option Ex | 1,926 | 155.57 | 299,627 |
| 2022-08-08 | Bhatia Sangeeta N. (Director) | Sale | 621 | 292.97 | 181,935 |
| 2022-08-08 | Altshuler David (EVP, Global Research and CSO) | Sale | 1,304 | 292.80 | 381,811 |
| 2022-08-08 | Altshuler David (EVP, Global Research and CSO) | Option Ex | 1,304 | 187.53 | 244,539 |
| 2022-07-29 | Bhatia Sangeeta N. (Director) | Sale | 621 | 279.58 | 173,617 |
| 2022-07-25 | Leiden Jeffrey M (Executive Chairman) | Sale | 132,079 | 281.39 | 37,165,181 |
| 2022-07-25 | Leiden Jeffrey M (Executive Chairman) | Option Ex | 60,342 | 91.05 | 5,494,139 |
| 2022-07-19 | Altshuler David (EVP, Global Research and CSO) | Sale | 17,865 | 288.18 | 5,148,246 |
| 2022-07-19 | Altshuler David (EVP, Global Research and CSO) | Option Ex | 17,765 | 171.55 | 3,047,585 |
| 2022-06-24 | Kewalramani Reshma (CEO & President) | Sale | 11,689 | 291.30 | 3,405,005 |
| 2022-05-16 | Liu Joy (SVP, General Counsel) | Sale | 133 | 252.61 | 33,597 |
| 2022-05-16 | Sanna Bastiano (EVP, Cell & Genetic Therapies) | Sale | 45 | 252.56 | 11,365 |
| 2022-05-16 | Arbuckle Stuart A (EVP, COO) | Sale | 133 | 250.37 | 33,298 |
| 2022-05-04 | Sanna Bastiano (EVP, Cell & Genetic Therapies) | Sale | 36 | 275.09 | 9,903 |
| 2022-05-02 | Sanna Bastiano (EVP, Cell & Genetic Therapies) | Sale | 320 | 259.66 | 83,090 |
| 2022-05-02 | Bhatia Sangeeta N. (Director) | Sale | 737 | 259.81 | 191,479 |
| 2022-05-02 | Arbuckle Stuart A (EVP, COO) | Sale | 306 | 263.98 | 80,777 |
| 2022-05-02 | Wagner Charles F Jr (EVP & Chief Financial Officer) | Sale | 343 | 259.61 | 89,047 |
| 2022-04-29 | Liu Joy (SVP, General Counsel) | Sale | 120 | 275.70 | 33,084 |
| 2022-04-25 | Ambrose Kristen (SVP & Chief Accounting Officer) | Sale | 327 | 269.25 | 88,046 |
| 2022-04-18 | Lee Yuchun (Director) | Sale | 2,000 | 284.68 | 569,360 |
| 2022-04-18 | Lee Yuchun (Director) | Option Ex | 2,000 | 81.54 | 163,080 |
| 2022-04-14 | Lee Yuchun (Director) | Sale | 2,000 | 289.45 | 578,906 |
| 2022-04-14 | Lee Yuchun (Director) | Option Ex | 2,000 | 81.54 | 163,080 |
| 2022-04-13 | Lee Yuchun (Director) | Sale | 2,000 | 286.70 | 573,406 |
| 2022-04-13 | Lee Yuchun (Director) | Option Ex | 2,000 | 81.54 | 163,080 |
| 2022-04-13 | Leiden Jeffrey M (Executive Chairman) | Sale | 15,789 | 289.04 | 4,563,652 |
| 2022-04-12 | Lee Yuchun (Director) | Sale | 2,000 | 281.17 | 562,340 |
| 2022-04-12 | Lee Yuchun (Director) | Option Ex | 2,000 | 81.54 | 163,080 |
| 2022-04-11 | Lee Yuchun (Director) | Sale | 2,000 | 280.67 | 561,340 |
| 2022-04-11 | Lee Yuchun (Director) | Option Ex | 2,000 | 81.54 | 163,080 |
| 2022-04-08 | Bhatia Sangeeta N. (Director) | Sale | 1,907 | 280.20 | 534,341 |
| 2022-04-08 | Bhatia Sangeeta N. (Director) | Option Ex | 1,907 | 125.71 | 239,728 |
| 2022-04-08 | Lee Yuchun (Director) | Sale | 2,000 | 278.41 | 556,820 |
| 2022-04-08 | Lee Yuchun (Director) | Option Ex | 2,000 | 81.54 | 163,080 |
| 2022-04-08 | Mcglynn Margaret G (Director) | Sale | 5,000 | 280.84 | 1,404,199 |
| 2022-04-08 | Mcglynn Margaret G (Director) | Option Ex | 5,000 | 127.54 | 637,700 |
| 2022-04-07 | Sanna Bastiano (EVP, Cell & Genetic Therapies) | Sale | 561 | 276.37 | 155,045 |
| 2022-04-07 | Lee Yuchun (Director) | Sale | 2,000 | 275.04 | 550,076 |
| 2022-04-07 | Lee Yuchun (Director) | Option Ex | 2,000 | 81.54 | 163,080 |
| 2022-04-06 | Lee Yuchun (Director) | Sale | 2,000 | 270.71 | 541,430 |
| 2022-04-06 | Lee Yuchun (Director) | Option Ex | 2,000 | 81.54 | 163,080 |
| 2022-04-05 | Sanna Bastiano (EVP, Cell & Genetic Therapies) | Sale | 3,163 | 275.23 | 870,552 |
| 2022-04-05 | Lee Yuchun (Director) | Sale | 2,000 | 271.84 | 543,684 |
| 2022-04-05 | Lee Yuchun (Director) | Option Ex | 2,000 | 81.54 | 163,080 |
| 2022-04-04 | Sanna Bastiano (EVP, Cell & Genetic Therapies) | Sale | 562 | 267.76 | 150,483 |
| 2022-04-04 | Lee Yuchun (Director) | Sale | 2,000 | 267.14 | 534,280 |
| 2022-04-04 | Lee Yuchun (Director) | Option Ex | 2,000 | 81.54 | 163,080 |
| 2022-04-01 | Wagner Charles F Jr (EVP & Chief Financial Officer) | Sale | 2,582 | 264.56 | 683,083 |
| 2022-03-31 | Mcglynn Margaret G (Director) | Sale | 5,000 | 262.21 | 1,311,035 |
| 2022-03-31 | Mcglynn Margaret G (Director) | Option Ex | 5,000 | 127.54 | 637,700 |
| 2022-03-17 | Sanna Bastiano (EVP, Cell & Genetic Therapies) | Sale | 2,122 | 250.06 | 530,627 |
| 2022-03-17 | Tatsis Ourania (EVP, Chief Reg. & Quality Off.) | Sale | 2,833 | 250.67 | 710,148 |
| 2022-03-17 | Wagner Charles F Jr (EVP & Chief Financial Officer) | Sale | 3,171 | 250.59 | 794,620 |
| 2022-02-25 | Tatsis Ourania (EVP, Chief Reg. & Quality Off.) | Sale | 325 | 230.94 | 75,056 |
| 2022-02-18 | Tatsis Ourania (EVP, Chief Reg. & Quality Off.) | Sale | 519 | 231.37 | 120,078 |
| 2022-02-18 | Altshuler David (EVP, Global Research and CSO) | Sale | 4,312 | 231.08 | 996,416 |
| 2022-02-14 | Altshuler David (EVP, Global Research and CSO) | Sale | 2,444 | 232.02 | 567,056 |
| 2022-02-02 | Sanna Bastiano (EVP, Cell & Genetic Therapies) | Sale | 1,040 | 252.61 | 262,718 |
| 2022-02-02 | Altshuler David (EVP, Global Research and CSO) | Sale | 4,660 | 251.08 | 1,170,018 |
| 2022-02-02 | Altshuler David (EVP, Global Research and CSO) | Option Ex | 4,660 | 86.52 | 403,183 |
| 2022-02-02 | Wagner Charles F Jr (EVP & Chief Financial Officer) | Sale | 2,944 | 250.07 | 736,206 |
| 2022-01-28 | Mcglynn Margaret G (Director) | Sale | 5,000 | 242.09 | 1,210,475 |
| 2022-01-28 | Mcglynn Margaret G (Director) | Option Ex | 5,000 | 127.54 | 637,700 |
| 2021-11-15 | Arbuckle Stuart A (EVP, COO) | Sale | 3 | 187.40 | 562 |
| 2021-11-15 | Altshuler David (EVP, Global Research and CSO) | Sale | 34 | 187.16 | 6,363 |
| 2021-11-15 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 51 | 187.13 | 9,543 |
| 2021-08-19 | Kewalramani Reshma (CEO & President) | Buy | 10,000 | 195.74 | 1,957,400 |
| 2021-08-02 | Sachs Bruce I (Director) | Buy | 15,000 | 197.91 | 2,968,650 |
| 2021-06-02 | Bhatia Sangeeta N. (Director) | Sale | 559 | 209.99 | 117,384 |
| 2021-05-17 | Altshuler David (EVP, Global Research and CSO) | Sale | 79 | 216.25 | 17,083 |
| 2021-05-03 | Sanna Bastiano (EVP, Cell & Genetic Therapies) | Sale | 960 | 218.44 | 209,707 |
| 2021-04-05 | Sanna Bastiano (EVP, Cell & Genetic Therapies) | Sale | 1,686 | 214.44 | 361,545 |
| 2021-03-05 | Liu Joy (SVP, General Counsel) | Sale | 5,141 | 209.99 | 1,079,543 |
| 2021-03-01 | Silva Paul M (SVP & Chief Accounting Officer) | Sale | 2,782 | 211.80 | 589,233 |
| 2021-02-25 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Sale | 3,028 | 213.79 | 647,356 |
| 2021-02-25 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Sale | 3,634 | 214.00 | 777,657 |
| 2021-02-25 | Altshuler David (EVP, Global Research and CSO) | Sale | 3,028 | 213.79 | 647,365 |
| 2021-02-25 | Silva Paul M (SVP & Chief Accounting Officer) | Sale | 1,080 | 213.87 | 230,982 |
| 2021-02-25 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 3,586 | 214.25 | 768,286 |
| 2021-02-18 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Sale | 7,825 | 211.98 | 1,658,743 |
| 2021-02-18 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Sale | 7,825 | 211.89 | 1,658,062 |
| 2021-02-18 | Altshuler David (EVP, Global Research and CSO) | Sale | 7,825 | 211.95 | 1,658,508 |
| 2021-02-18 | Silva Paul M (SVP & Chief Accounting Officer) | Sale | 4,295 | 211.50 | 908,379 |
| 2021-02-18 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 9,264 | 211.63 | 1,960,568 |
| 2021-02-11 | Sanna Bastiano (EVP, Cell & Genetic Therapies) | Sale | 1,686 | 210.93 | 355,619 |
| 2021-02-11 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Sale | 5,156 | 211.23 | 1,089,086 |
| 2021-02-11 | Altshuler David (EVP, Global Research and CSO) | Sale | 5,283 | 211.04 | 1,114,950 |
| 2021-02-11 | Silva Paul M (SVP & Chief Accounting Officer) | Sale | 1,498 | 210.88 | 315,905 |
| 2021-02-05 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Sale | 1,930 | 215.00 | 414,950 |
| 2021-02-05 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Option Ex | 1,930 | 86.52 | 166,983 |
| 2021-02-03 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Sale | 400 | 216.91 | 86,762 |
| 2021-02-03 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Option Ex | 400 | 86.52 | 34,608 |
| 2021-02-03 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Sale | 1,554 | 214.25 | 332,944 |
| 2021-02-03 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Option Ex | 1,554 | 86.52 | 134,452 |
| 2020-11-16 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Sale | 91 | 223.51 | 20,339 |
| 2020-11-16 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Sale | 7 | 223.29 | 1,563 |
| 2020-11-16 | Altshuler David (EVP, Global Research and CSO) | Sale | 38 | 223.45 | 8,490 |
| 2020-11-16 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 42 | 223.57 | 9,389 |
| 2020-11-10 | Sachs Bruce I (Director) | Buy | 15,000 | 217.58 | 3,263,745 |
| 2020-11-04 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Sale | 2,330 | 218.47 | 509,030 |
| 2020-11-04 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Option Ex | 2,330 | 86.52 | 201,591 |
| 2020-11-03 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Sale | 1,553 | 212.15 | 329,473 |
| 2020-11-03 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Option Ex | 1,553 | 86.52 | 134,365 |
| 2020-10-05 | Bhatia Sangeeta N. (Director) | Sale | 10,516 | 265.69 | 2,793,964 |
| 2020-10-05 | Bhatia Sangeeta N. (Director) | Option Ex | 8,729 | 126.68 | 1,105,789 |
| 2020-08-06 | Kewalramani Reshma (CEO & President) | Sale | 2,073 | 271.38 | 562,579 |
| 2020-08-06 | Kewalramani Reshma (CEO & President) | Option Ex | 2,073 | 171.55 | 355,623 |
| 2020-08-06 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Sale | 1,223 | 271.37 | 331,885 |
| 2020-08-06 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Option Ex | 1,223 | 155.57 | 190,262 |
| 2020-08-06 | Altshuler David (EVP, Global Research and CSO) | Sale | 1,223 | 271.37 | 331,885 |
| 2020-08-06 | Altshuler David (EVP, Global Research and CSO) | Option Ex | 1,223 | 155.57 | 190,262 |
| 2020-08-06 | Silva Paul M (SVP & Controller) | Sale | 1,078 | 271.51 | 292,693 |
| 2020-08-06 | Silva Paul M (SVP & Controller) | Option Ex | 1,078 | 171.55 | 184,930 |
| 2020-08-03 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Sale | 2,330 | 278.17 | 648,143 |
| 2020-08-03 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Option Ex | 2,330 | 86.52 | 201,591 |
| 2020-08-03 | Altshuler David (EVP, Global Research and CSO) | Sale | 2,330 | 278.54 | 648,993 |
| 2020-08-03 | Altshuler David (EVP, Global Research and CSO) | Option Ex | 2,330 | 86.52 | 201,591 |
| 2020-08-03 | Silva Paul M (SVP & Controller) | Sale | 809 | 278.06 | 224,954 |
| 2020-08-03 | Silva Paul M (SVP & Controller) | Option Ex | 809 | 86.52 | 69,994 |
| 2020-08-03 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 1,941 | 278.13 | 539,850 |
| 2020-08-03 | Sachdev Amit (EVP, Chief Patient Officer) | Option Ex | 1,941 | 86.52 | 167,935 |
| 2020-07-13 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Sale | 2,125 | 290.55 | 617,414 |
| 2020-07-13 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Option Ex | 2,125 | 90.29 | 191,866 |
| 2020-07-13 | Silva Paul M (SVP & Controller) | Sale | 860 | 290.72 | 250,020 |
| 2020-07-13 | Silva Paul M (SVP & Controller) | Option Ex | 860 | 90.29 | 77,649 |
| 2020-07-10 | Wagner Charles F Jr (EVP & Chief Financial Officer) | Sale | 700 | 292.65 | 204,854 |
| 2020-07-07 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Sale | 2,786 | 300.00 | 835,800 |
| 2020-07-07 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Option Ex | 2,786 | 171.55 | 477,938 |
| 2020-06-30 | Leiden Jeffrey M (Executive Chairman) | Sale | 32,792 | 287.72 | 9,434,914 |
| 2020-06-02 | Bhatia Sangeeta N. (Director) | Sale | 952 | 282.96 | 269,379 |
Insider trading activities including stock purchases, stock sales, and option exercises of VRTX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Vertex Pharmaceuticals Inc / Ma (symbol VRTX, CIK number 875320) see the Securities and Exchange Commission (SEC) website.